Microbot Medical (NASDAQ:MBOT) Shares Pass Above Two Hundred Day Moving Average – Here’s Why

Posted by Defense World Staff on Apr 2nd, 2025

Shares of Microbot Medical Inc. (NASDAQ:MBOT – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.33 and traded as high as $1.53. Microbot Medical shares last traded at $1.49, with a volume of 374,393 shares.

Analyst Ratings Changes

Separately, HC Wainwright increased their target price on shares of Microbot Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, January 24th.

View Our Latest Research Report on Microbot Medical

Microbot Medical Price Performance

The stock has a market cap of $51.77 million, a P/E ratio of -1.86 and a beta of 1.60. The company has a fifty day moving average of $1.73 and a 200 day moving average of $1.33.

Microbot Medical (NASDAQ:MBOT – Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). As a group, analysts anticipate that Microbot Medical Inc. will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Microbot Medical

An institutional investor recently bought a new position in Microbot Medical stock. Renaissance Technologies LLC bought a new position in Microbot Medical Inc. (NASDAQ:MBOT – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 105,658 shares of the biotechnology company’s stock, valued at approximately $118,000. Renaissance Technologies LLC owned approximately 0.52% of Microbot Medical at the end of the most recent reporting period. 16.30% of the stock is owned by institutional investors and hedge funds.

About Microbot Medical

(Get Free Report)

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.